Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This could be similar to Anatabine Citrate which has had some positive effects for CNS dementia conditions.... It is derived from Tabbaco so this indicates some similarity to this new enzyme,,
Thanks for the reply golden .... For the longs here I hope the min conversion (what ever the exact price is) will hold it from spiralling down... I do like the science here and will continue to do more DD...I recently sold out of another ex OTC Biotech ... which required even more patience than RCPI ... called anavex... anyways good luck to all longs here....
The edgar documents detailing the financing do not indicate that there is a minimum price to convert to shares...You have said this before but this does not make sense.... show a link if you have info showing min price...
I agree with most of your other comments though....
It was reported from the recent shareholder meeting that Missling mentioned that S1 receptors are located all over the human body, in many varied cell types... Interesting results from Harvard Medical on figuring out the structure of S1 ... this is very valuable info to all companies focusing on the receptor ...including avxl...
anyone here knowledgeable on past financing terms?
Went to look at 2015 10Q from edgar to look at terms of 20 m financing oct 15 2015...
-it look like the note holders can convert as much as they want , up to 20m, ewhwther or not RCPI has access to the funds from restricted accounts or not ...is this the case?
-how much has the company withdrawn of the 20m? estimates? I am guessing about 6 mill...
-it does appear they can buy out the note holders, and if they can use the remaining funds in the restricted accounts (about 14 m) then they would have to only raise about 3 or 4 million to buy this deal out ...I am assuming about 3 m has already been converted to shares...
Those using the NSS strategy to pummel small emerging companies are killing the goose that lays golden eggs for them....This judgement affirms that. excessive greed, and disregard for public interest will be self correcting .... Also the political winds are changing and the spotlight is shining on this festoring sore.... Most other big economies have already banned (or or in the process) NSS completely...
Excellent Post! and very Spot on ...Just to add Basparks, ...This is also why the like a stock to be "channel trading" well below its true value by a significant amount .....then when they bash it down , it can overcome the negativity they hurl at it, and recover up based on value and continue the channel volatility... AVXL is insanely undervalued, and IMO even the regular knowledgeable posters here have become conditioned to the "new (and artificial) reality". of where value lies...
Take down targets partnership negotiations...to weaken price expectations of avxl management...
273 has the one two punch due to the metabolite affinities...
Anavex has "in-house" International patent IP legal staff... Question to consider: Would a company that did not feel strongly about its science dedicate in-house staff to this function (out-sourcing is much simpler)? and in making this decision, look at the quality of the Anavex SAB to make this decision...
From AVXL web site:
"Steffen Thomas, PhD, a director of Anavex, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich."
salt and pepper SHAKER of basher cartel brain:
Is uncle JC the brain, maybe/likely, but the false lawsuits and basher articles reminds me of a giant salt and pepper SHAKER set, skillfully used by the head brain (likely a bald guy) of the basher cartel... The salt and pepper shakers are bottomless... False law suits are salt and basher articles are pepper... There are many other tools the bald guy uses but the near bottomless salt and pepper shakers are key to his operation...
MF passed the baton to Geo.... They pass the baton after the impact effect has worn off of having a fresh "stock analyst firm" present ....BTW this is the worst piece I have ever seen from Geo ...nice how the geo author speaks so positive about AF.... It is also factually inaccurate...for example it says AVXL ran up from 4s to high 5s on the back of a Orphan Drug promotion....pretty funny...also praises MS as a brilliant investor, again funny stuff... Lastly add in the timing and it equates to A big black eye for Geo ...
ppietrz from ymb.... he also clarifies when he uses the word "cure" he does not mean it in the literal sense of the word....
"All those who tell you to wait and look for the signs of efficacy later in P3 placebo controlled trials are missing the big point of already revealed efficacy, which is in line with preclinical. What happens with A2-73 happen only for the best drugs. In conclusion A2-73 is not only a drug curing AD but also a cognitive enhancer - essential to good mental health."
He also mentioned that in pre-clinicals healthy mice given 273 performed better than healthy mice undosed....i.e. the cognitive enhancer......
comment from ppietrz yob
Data is not the only important information that goes into pricing a bio stock...The price (theoretically) represents ALL known information that indicates the probability of success with a given market size and derived cash flow.... Clearly, having patients respond to a drug in trials with improvement news, of any kind, reflects positively on the probability of success of a given drug, and this (with manipulation absent) has a proportional positive impact on the share price... This is basic knowledge in financial analysis and so am surprised to hear Closetinvestor repeat this logic over and over again today...
Helpful to build a swell of support from non-financial, non-scientific community towards potential remedies for major disease categories...Good first step (it seems in this regard) by the Herald...
1588 - or a significant number for certain algos (programed to recognize) to initiate after hours trading sequence..
1588 -- a code among market manipulators or market makers whom know their phones are tapped..
Agree about Japan, with you and Xena 100%... Additionally some of the early reseach in sigma 1 M1 science , that is foundational to avxl science actually came out of Japan ... check the 10 year old ish written papers... and also Otsuka , just 12 months ago bought out a USA co with a partial sigma 1 science product for about $3 billion..(actually this co was also bashed by the same cartel of greed)...
In Japan they have a regulatory pathway, of conditional approval where you go straight to market after phase 2 .... Couple this with their dire need of AD products, would suggest a very fast pathway to market their also ... With the size of the Japanese market (160 million, and an aging demographic) it has the legitimate opportunity to be a very profitable venture, on that country alone....
Agree 100% .... most/many can not see actual cause and effect linkage and assume due to timing that article caused the short fall ... the ramifications of the contents of his message, taken from the simple meaning of his words, had zero effect ...... He could have almost said anything as long as it seemed vaguely on topic..... another aspect is that since he has so many blind followers, he does not really even have to be "on topic". with this grouping of players..... So he has an effect from blind followers, and maybe even algos, that have his reports programmed into them somehow, what he says means very little --- and as his role is becoming more widely known, his effect is diminishing...soon the algos will need re-writing.....
Who will be drive the bus driver in AD partnership:
I would like to see AVXL, with it very strong list on its SAC, direct P3 operations on AD.... I have seen quite a few companies do partnerships that appear to just be a means of silencing a company and slowing development.... news drys right up and things slow way down...not always but as i said quite a few ... the devil is in the detail in a partnership contract... trusting CM, with his ample background and acumen in this regard...AD is too big to be stifled in a dodgy partnership...
Japanese culture is very honourably and trustworthy also .... this is not a moot point... Agree and if AVXL is smart they can sell off some non-core markets (mainly just marketing rights) to pay for P2b/3...Your comment about manufacturing is interesting...and a Japanese co could be designated world wide manufacturer and sales agent for their home country, (one or both) for an upfront fee.....and thereby AVXL retaining NA and W.Europe .... Lastly, Japan is desperate for a useful AD drug given their demographic .... and they are more compassionate about helping their citizens... In Japan things like cartels trying to slow down a potential remedy being developed for AD would very simply not be allowed... AVXL , and other promising small bios attacked on US exchanges, may also have to forge a different financing pathway until things are cleaned up (which at some point they will be)... and Japan could hold the key to this different pathway...maybe AVXL can show the way...
retail is being conditioned, over and over, to think sell on news..
The constant bashing and pullbacks on news is creating a sense of an inevitable pull back on any good news..this is a type of conditioning that is fully set in here now... and self described successful swing traders here have boosted this conditioning even further.... it looks like they can wipe out a high percentage of retail here , on news, of their choice.... when they choose ... a traders dream until the chosen moment...
The ODD bash today was an effort to create the opportunity to unwind the short positions (legal and other wise) opened to hold good news back last week (end)...knowing good news is coming out soon and time for those positions is running out ...the subject matter of bash was as solid as the legs of a newborn....
Looks like they are still willing to use NSS while under close scrutiny.....
MF articles were timed to counter
very good news twice,recently ,they had an article out right after each ...the orphan designation and the Heptares deal... If these two very positive news events had not happened MF would have been quiet...When articles are written to counter good news it is all telling.....
The recipe is simple, and is exactly the same every time.... counter good news immediately with bash pieces and sprinkle on just enough fake liquidity (when needed) to achieve a pull back fade...
bingo !!!!
Also, another very possible scenery is that if Allergan is very serious about this class of drugs (which they appear to be) maybe they still are the suitor for AVXL, and want as many shots on goal as possible in the niche and with less competition .... much like AVXL going after 371 after they already had 273 .....If you assemble a team of experts in the niche why not spread the top talent over several drugs in the specialty... which is what avxl has done and Allergan may be also headed this way.... and still after avxl......and remember when you buy a company usually you have a crack at the top talent...look at what an avxl purchase could net Allergan in talent... it may be a no brainer...
Allergan may have been a backer of the misfit gang bashing avxl....but could not get CM to crumble...
rememberhes is paid , in a round about way, to be the mouth piece , trumpeter, and symbolic (only) leader, of the basher cartel and has many shorters following and counting on him ( blindly I might add).... and so in this situation he has to , always maintain his negative stance and chatter....... if you do some dd on him you will see he has made glowing comments about companies he supported that received orphan status....The only way he would change his stance is if a partnership or buyout, or NDA approval goes through...resulting in game over... Those paying his way demand his status quo...
From YMB minutes ago......
"Today Allergan Paid $3.3 Billion for Heptares Phase 1b Drug (Only 28 patients), What is AVXL Worth?
Fiercebiotech article title .."Solo again, Allergan strikes a $3.3B deal on Heptares' Alzheimer's portfolio"
April 6, 2016 | By John Carroll
Just hours after Allergan backed away from a $160 billion merger with Pfizer, the company has bounced back with a $3.3 billion licensing deal for global rights to a portfolio of drugs for neurological disorders from the UK's Heptares.
Here is what I think. AVXL has Phase 2a data in Alzheimers patients.and is worth MORE than Heptares. Here is why. Heptares has Phase 1b results that they reported in Feb 2016. However, it is not data showing improvement in cognition, only in 28 Healthy (not Alzheimers patients) and no evidence clinical efficacy, just evidence of brain activity in health patients.. NO COGNITIVE DATA. See details from Heptares Feb 2016 press release below....
The Phase 1b precision medicine study involved 28 healthy elderly subjects who received different doses of
HTL9936 and was designed to test the effect of drug on measures of brain activity while simultaneously monitoring side effects.
In the study, HTL9936 exhibited robust and statistically significant changes in brain electrical activity measured using multiple electroencephalography (EEG) biomarkers relevant to cognition, including effects on the P300 evoked response potential (p=0.0052). These pro-cognitive effects were seen at low doses and low blood concentrations that were safe and well tolerated"""
CBD.... watch closely at 20:30 from the video on "Scientist" you link...interesting how the doctor mentions doing research in a small country with limited budget when competing against "major groups" and picking useful but unique pathways.... reminds me of Dr. V in Greece way back...
The 194 mill you mention is not debt (they do not owe this) it is accumulated deficit (what they have lost operationally to date) .... this is actually a very big plus for AMDA since they can sell the co to another co and they can use this AD as an offset to future taxes... thats why IMO the co is worth $100 million with out the business even considered.... Debt is what they owe....which is like 17 or 18 million... approx.... Once again this AD is totally under the radar and has huge value to another medical implant company ... likely around 100 million and current market cap is like 18 million...very comical actually..
not sure where you get your numbers but they do not have 194 million of debt ... only about 10% of that...
Ty and Sonny are both responsible for the last recent round of very unnecessary toxic financing (it has their name stamped on it clearly) ... and Sonny since he was a director , when the previous toxic financing with Hercules and Magna, is also responsible for that ... There are hundreds of billions of dollars looking for sound healthcare investments and even a very novice junior CFO or CEO could at anytime here have done a financing or refinancing at market terms.... with 20 million in sales and a very very bright future they obviously did not "WANT" market terms in their past financing(s)..... It would have been VERY easy to re-fi both Hercules and Magna, and with out the crazy Cash maintenance requirement of Hercules... and without the very unnecessary multi level warrant dilution with way over the top and unnecessarily complex terms.... The question is will they give away the company again with the next financing or will they try to break the very clear trail of financial incompetance (this is putting it mildly and you can likely connect the dots better here)....
Ironic that manipulators crash stock price; and then use what they actually caused, against the company , as a reason to launch volumes of fake lawsuits...... What a twisted web they weave....Again though, the obvious shenanigans (in outlandish proportions) will ultimately cause a new level of regulator response (unlike in the past) and so the actors are now ultimately sealing their own fate....
so the more fake law suits the better, it only makes it more obvious to those watching...
BP is facing a huge patent cliff (many many blockbusters and prime drugs coming off patent) and poor results in their R&D departments (compared to much smaller but more agile and innovative companies) ...add to this the likely upcoming problems with drug pricing.. as a result BP is feeling stressed.... This is why they are now increasingly resorting to market manipulation (and colluding with various nefarious participants in the process) of small companies with promising drug tech ... this is not just AVXL but as Xena mentioned the whole lot of promising bios.....Their recent exesses will put this issue in the spotlight and it will soon self correct; but in the meantime, companies being continuously dogged by nefarious types, and continuing on after a big pullback, are an indication of where BP sees value... and make up for their own weak R&D programs,patent cliff, and cooling pricing climate....
Very similar to how MS and VRX have almost single handed, put drug prices in the negative spot light (and likely control by govt) for BP... and so in effect started a process that is self destructive ..... a very similar situation is unfolding where the actions of the "no-morels gang" colluding with BP , are very near setting off a self destructive process, by attracting too much negative attention to their rampant manipulation in the bio space... Whether it be Sanders or Trump, crusty politicians that cater to lobby groups like pharmacy, are loosing public support and new leaders (Sanders , Trumo( with the sense and mind set to make and implement sensible (but unpopular to lobby groups) direction changing programs.... They will squash this absurd manipulation when power is gained soon... all things that get out of control eventually are the cause for their own downfall....
BP funded shorting (carried out by the very infamous "no-morels gang") of this co on any, and all news, is an obvious pattern here... which was started post Nov. 7th... and continues today..... I think it is embarrassing for BP that such a small upstart can outshine them, after they have spent many Billions with zero results..... somebody has a complex....
LDIGGIDY..... thats the best post i have seen here recently... Investors have been so churned back and forth and upside down that they have totally lost sight of what this co is worth..and now just look at meaningless things like what share price was at at some point etc.... shake and bake to the extreme..
Yes and if Cardio meds are being developed for preventative and maintenance for cardio niches, it is fairly obvious that prevention and maintenance meds (that work) will also have a massive market, for mental health niches...